Oryzon Genomics S.A.

BME:ORY Stock Report

Market Cap: €93.9m

Oryzon Genomics Future Growth

Future criteria checks 5/6

Oryzon Genomics is forecast to grow earnings and revenue by 53.6% and 46.6% per annum respectively. EPS is expected to grow by 53.4% per annum. Return on equity is forecast to be -3.5% in 3 years.

Key information

53.6%

Earnings growth rate

53.4%

EPS growth rate

Biotechs earnings growth35.0%
Revenue growth rate46.6%
Future return on equity-3.5%
Analyst coverage

Low

Last updated21 Nov 2024

Recent future growth updates

Recent updates

Growth Investors: Industry Analysts Just Upgraded Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts By 54%

Oct 03
Growth Investors: Industry Analysts Just Upgraded Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts By 54%

Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch

Jun 09
Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch

Is Oryzon Genomics (BME:ORY) Using Too Much Debt?

Apr 04
Is Oryzon Genomics (BME:ORY) Using Too Much Debt?

Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts

Jul 24
Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts

Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?

May 01
Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?

Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?

Feb 26
Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?

If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns

Jan 04
If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns

Earnings and Revenue Growth Forecasts

BME:ORY - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20277036-20N/A3
12/31/20266-9-19N/A3
12/31/202514-6-16N/A4
12/31/20244-4-13N/A4
9/30/202416-5N/AN/AN/A
6/30/202412-4-14-2N/A
3/31/202415-3N/AN/AN/A
12/31/202316-4-17-1N/A
9/30/202317-4N/AN/AN/A
6/30/202317-4-21-3N/A
3/31/202317-5N/AN/AN/A
12/31/202217-5-17-2N/A
9/30/202210-3N/AN/AN/A
6/30/202214-5-15-3N/A
3/31/202212-5N/AN/AN/A
12/31/202112-5-18-4N/A
9/30/202111-4N/AN/AN/A
6/30/202110-4-17-4N/A
3/31/20217-5N/AN/AN/A
12/31/202012-4-17-6N/A
9/30/202012-4N/AN/AN/A
6/30/202013-4-16-4N/A
3/31/202013-4N/AN/AN/A
12/31/201912-4-15-4N/A
9/30/201910-4N/AN/AN/A
6/30/20199-4-11-3N/A
3/31/20198-2N/AN/AN/A
12/31/20188-1-9-1N/A
9/30/20187-2N/AN/AN/A
6/30/20186-2N/A-5N/A
3/31/20186-6N/AN/AN/A
12/31/20175-6N/A-6N/A
9/30/20176-6N/AN/AN/A
6/30/20176-6N/A-4N/A
3/31/20175-6N/AN/AN/A
12/31/20165-6N/A-5N/A
9/30/20166-5N/AN/AN/A
6/30/20166-4N/A-1N/A
3/31/20168-1N/AN/AN/A
12/31/20158-1N/A1N/A
9/30/20158-1N/AN/AN/A
6/30/20157-1N/AN/AN/A
3/31/2015112N/AN/AN/A
12/31/2014198N/A15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).

Earnings vs Market: ORY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ORY is expected to become profitable in the next 3 years.

Revenue vs Market: ORY's revenue (46.6% per year) is forecast to grow faster than the Spanish market (5% per year).

High Growth Revenue: ORY's revenue (46.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ORY is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 07:19
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oryzon Genomics S.A. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arron AatkarEdison Investment Research
Joaquin Garcia-QuirosJB Capital Markets
Lucy-Emma Mary Codrington-BartlettJefferies LLC